# China NMPA Drug Inspection - Hainan Shounanshan Ginseng Industry Co., Ltd. - dodder

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hainan-shounanshan-ginseng-industry-co-ltd/aeaebfcd-780b-4912-ace5-bcba9b2e3ec7/
Source feed: China

> China NMPA drug inspection for Hainan Shounanshan Ginseng Industry Co., Ltd. published February 23, 2017. Drug: dodder. This document, an announcement from China's State Administration for Market Regulation (NMPA) dated February 23, 2017, d

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 33 of 2017 from the State Administration of Traditional Chinese Medicine regarding 23 batches of substandard prepared slices of traditional Chinese medicine.
- Company Name: Hainan Shounanshan Ginseng Industry Co., Ltd.
- Publication Date: 2017-02-23
- Drug Name: dodder
- Action Taken: The relevant provincial (autonomous region, municipality) food and drug administrations have taken control measures such as sealing and seizing, requiring enterprises to suspend sales and use, recall products, and rectify the situation. The provincial (autonomous region, municipality) food and drug administrations where the production enterprises are located have initiated investigations into the illegal acts of producing and selling substandard products by the aforementioned enterprises in accordance with Articles 73, 74, and 75 of the "Drug Administration Law of the People's Republic of China," made penalty decisions, reported the penalty results to the State Administration for Market Regulation, and made them public, punishing the relevant responsible persons.
- Summary: This document, an announcement from China's State Administration for Market Regulation (NMPA) dated February 23, 2017, detailed findings of substandard traditional Chinese medicine (TCM) decoction pieces. Investigations by the Guangdong Provincial Institute for Drug Control identified 23 batches of unqualified Cuscuta chinensis (Dodder Seed), including its salted form, produced by 22 companies. Prominent among these was Hainan Shounanshan Ginseng Industry Co., Ltd. The primary violations involved failures to meet quality standards outlined in the *Pharmacopoeia of the People's Republic of China* (2010 and 2015 Editions). Specific deficiencies were noted in product appearance, identification tests (including microscopic characteristics and thin-layer chromatography), content determination, and impurities such as acid-insoluble ash and total ash. Following these findings, provincial food and drug administrations initiated control measures, including product sealing and seizure. The affected companies were mandated to cease sales, recall products, and implement rectifications. Operating under the *Drug Administration Law of the People's Republic of China* (Articles 73, 74, 75), local authorities were directed to investigate the illegal production and sale, issue penalty decisions within one month, and report outcomes to the NMPA for public disclosure. Provisions were also made for companies to dispute product authenticity, triggering further investigation and potential severe penalties if culpability was confirmed.

Company: https://www.globalkeysolutions.net/companies/hainan-shounanshan-ginseng-industry-co-ltd/12f0a50e-af9a-4133-9303-7fbdd9736ec5/